MeiraGTx Holdings Prices Underwritten Offering Of 11,111,111 Of Its Ordinary Shares At $9/Shr; Gross Proceeds Expected To Be ~$100M

MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of

MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of $9.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by MeiraGTx.

The Company believes that the net proceeds from this offering, together with its existing cash and cash equivalents, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements, including potential commercial launches of bota-vec for the treatment of X-linked retinitis pigmentosa and AAV-hAQP1 for the treatment of radiation-induced xerostomia, in each case if approved, into the second half of 2028.

BofA Securities and Goldman Sachs & Co. LLC are acting as joint book-running managers and Raymond James is acting as co-manager for the offering. The offering is expected to close on or about April 17, 2026, subject to customary closing conditions.